Trial data showed that Tagrisso, AstraZeneca’s lung cancer therapy, cut the risk of death by more than half in patients with a certain form of lung cancer and diagnosed early enough to have the tumor surgically removed.

In a 682-patient trial called ADAURA, Tagrisso was evaluated against a placebo in earlier-stage EGFR-mutated NSCLC patients who had undergone surgery to remove their primary tumor.

The majority of such patients eventually see their cancer return despite surgery and add-on chemotherapy.

In the trial, Tagrisso or a placebo was given to patients to assess whether the AstraZeneca therapy could keep their cancer at bay.

Data showed Tagrisso slashed the risk of death by 51% compared to placebo.

Read the full article here.